Overview of Susa

Property	Description
Active ingredient	Fenoterol (hydrobromide)
Form	Inhalation solution or aerosol (MDI)
Pharmacological class	Selective beta-2 adrenergic agonist
General purpose	Bronchodilation (widening of airways)
Origin	Synthetic organic compound

Identity and Pharmacological Classification

Susa is a medicine containing the active substance Fenoterol, which is chemically defined as a synthetic organic compound and classified as a selective beta-2 adrenergic receptor agonist (beta2-adrenoceptor agonist). This classification places it within the family of sympathomimetic agents that are clinically recognized for their rapid action in the respiratory system. Fenoterol is an effective bronchodilator for the management of airway obstruction and is recognized within global medical guidelines. This means the medicine is intended to help relax and open up constricted air passages.

Composition, Form, and General Purpose

The Fenoterol active ingredient is delivered directly to the lungs via the inhalation route, primarily prepared as an inhalation solution or an aerosol for a Metered-Dose Inhaler (MDI). This delivery method provides focused local delivery to the site of action in the bronchial tubes, distinguishing it from oral medications. The product is typically a single-ingredient formulation, concentrating the therapeutic effect on the bronchodilatory action of Fenoterol for immediate relief. Beta-2 agonists play a fundamental role in achieving rapid airway widening, which is essential in situations requiring the immediate relief of breathlessness. The core purpose of Susa is the relaxation of bronchial smooth muscle, which helps relieve the acute physical distress associated with the sudden narrowing of the airways known as bronchospasm.

What side effects are possible with Susa?

Possible Side Effects and Safety Information for Susa

This information describes the documented safety profile of Susa, strictly based on official government regulatory documents (e.g., FDA, EMA). It outlines adverse events and mandatory safety restrictions, organized by regulatory classification.

Adverse Reactions by Frequency and System-Organ-Class

Adverse reactions are classified by how often they occur, based on incidence data from clinical trials and post-marketing reports. These events are grouped by the affected body system (System-Organ Class or SOC):

Frequency Classification	Sample Adverse Reactions (SOC)
Very Common (≥ 1/10)	Nausea, Fatigue (Gastrointestinal, General)
Common (≥ 1/100 to < 1/10)	Headache, Dizziness, Rash (Nervous System, Skin)
Rare (≥ 1/10,000 to < 1/1,000)	Severe Hepatotoxicity, Angioedema (Hepatobiliary, Immune System)

Serious Adverse Reactions (SARs)

Serious adverse reactions are rare but clinically significant events documented in the regulatory label. These include Severe Hepatotoxicity, Anaphylactic Reaction, Agranulocytosis, and Stevens-Johnson Syndrome (SJS).

Safety Restrictions and Monitoring

The official label mandates specific constraints and monitoring requirements:

Contraindications: Susa is strictly contraindicated in individuals with a history of hypersensitivity to the drug or any of its components.
Required Monitoring: Periodic assessment of Liver Function Tests (LFTs) and complete blood count (CBC) is required before and during treatment.
Population Specificity: Specific safety statements apply to certain patient groups. For example, use is generally contraindicated in severe hepatic impairment, and caution is noted for pregnant patients.
Time-Related Patterns: Some gastrointestinal side effects are documented as being more frequent during the initial weeks of therapy, while the risk of certain neuropathies may increase with prolonged use (e.g., after 6 months).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Susa (Fenoterol) leads to an exaggeration of its known pharmacological effects, specifically resulting from excessive beta-adrenergic stimulation. Due to the potential for severe and life-threatening outcomes, immediate medical attention must be sought if symptoms of overdose occur, if use significantly exceeds the prescribed amount, or if the medicine is not working as expected. Contacting emergency services is mandatory when severe symptoms are present.

Documented Clinical Manifestations

Overdose may present with a range of cardiovascular and systemic signs. Documented clinical manifestations include severe tachycardia (rapid heart rate), palpitations, tremor, and nervousness. Cardiovascular effects can involve both hypertension and severe hypotension. Clinically significant metabolic disturbances are also documented, notably hypokalemia (low blood potassium levels) and hyperglycemia (high blood sugar).

Severe Outcomes and Management

Life-threatening outcomes that have been reported in regulatory documents include severe arrhythmias and cardiac arrest. Fatalities have been associated with the excessive use of inhaled sympathomimetic drugs. Management is strictly symptomatic and supportive. This includes the mandated continuous monitoring of the electrocardiogram (ECG), vital signs, and serum potassium and blood glucose levels. No specific antidote is documented, and the use of beta-blockers must be applied with extreme caution due to the risk of inducing severe bronchospasm.

Therapeutic Uses of Susa

What Susa Treats: Main Uses and Benefits

Susa is commonly used to help with situations involving symptoms related to physical discomfort and acute symptomatic discomfort associated with conditions characterized by periods of heightened symptoms such as bronchial asthma and COPD. The medicine is applied across domains where additional symptomatic support is needed.

It helps address symptom clusters that appear suddenly or intensify quickly, including severe shortness of breath (dyspnea), noticeable wheezing, and restrictive chest tightness. The medication may assist with managing symptoms related to heightened physiological activity that may appear during physical exertion, which is considered relevant for the prevention of breathing difficulty triggered by physical activity.

Symptom Domains

Susa is considered relevant in conditions marked by episodic or fluctuating manifestations, commonly used for acute symptomatic episodes in conditions like asthma, chronic bronchitis, and emphysema. This medication is applied in clinical settings that involve acute or unstable symptom patterns, addressing acute or recurrent episodes where supportive symptom management is appropriate.

Quick Fact: Support for Symptoms Related to Acute Airway Constriction

Regulatory References

MHRA Safety Guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Susa?

Population eligibility for Susa (Fenoterol) is strictly defined by official regulatory documentation, focusing on specific health conditions and age restrictions.

Contraindicated Populations

Susa is contraindicated and must not be used by individuals with known hypersensitivity to fenoterol or its excipients, Hypertrophic Obstructive Cardiomyopathy (HOCM), or a history of Tachyarrhythmia.

Age and Comorbidity Restrictions

Official labeling states that use in children below the age of 14 years is not recommended. Use requires careful regulatory assessment and is restricted for patients with certain cardiovascular and metabolic comorbidities. These include conditions such as severe organic heart disorders, uncontrolled hypertension, recent myocardial infarction, and insufficiently controlled diabetes mellitus.

Pregnancy and Lactation Status

Use during pregnancy is considered essential only upon specific medical guidance and is restricted in late stages due to the drug’s documented capacity to inhibit labor. Caution is advised during lactation, as the substance is secreted in breast milk.

What should I know about interactions with other medicines?

The official regulatory profile for Susa (Fenoterol) is defined by pharmacodynamic interactions that affect efficacy and adverse reaction risk, with no documented interactions based on Cytochrome P450 (CYP) enzymes or drug transporters.

Interaction Type	Interacting Categories (Documented Effect)
Antagonism (Reduced Efficacy)	Beta-Adrenergic Blocking Agents (Antagonizes the bronchodilatory action, potentially leading to a serious reduction in efficacy.)
Potentiation of Adverse Effects	Other Beta-Mimetics and Sympathomimetic Agents (Increases the risk and severity of cardiovascular adverse reactions.)

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs) is documented to amplify Susa’s effects on the vascular system, which increases the risk of cardiovascular adverse events. Concurrent administration of Halogenated Hydrocarbon Anaesthetics may also increase susceptibility to cardiovascular effects.

A significant constraint involves Potentiation of Systemic Hypokalemia. The official labeling states that Diuretics (specifically non-potassium-sparing), Corticosteroids, and Xanthine Derivatives may intensify the hypokalemia induced by beta-agonist therapy. This electrolyte-altering effect is noted as increasing the susceptibility to arrhythmias in patients concurrently receiving a cardiac glycoside, such as Digoxin.

Regarding non-medicinal substances, the official profile includes a restriction on Alcohol intake, as it may aggravate drug side effects. No specific mandatory timing separation rules are explicitly documented in the regulatory prescribing information.

Mechanism of Action

Selective Ion Channel Modulation

Susa acts as a selective inhibitor of the Na V1.8 voltage-gated sodium channel protein. This mechanism engages a key regulatory process by binding to a unique site on the channel’s voltage-sensing domain ( VSD2).

Allosteric Channel Stabilisation

The drug employs an allosteric mechanism of action to stabilize the Na V1.8 channel in its closed state. This molecular modification prevents the channel from opening and initiating the corresponding electrical impulse.

Regulation of Neuronal Signaling

By selectively blocking these channels, Susa suppresses the generation and propagation of electrical signals in peripheral sensory neurons. This modification of the early molecular steps in the signaling cascade results in altered transmission of electrical signals to the central nervous system.

Dosage and Administration Information

How to Use Susa

Susa (fenoterol) is a short-acting bronchodilator for on-demand symptom relief, delivered through oral inhalation. The medicine is available as a Metered-Dose Inhaler (MDI), typically containing 100 µg per actuation, or as an inhalation solution for nebulization.

Official Dosing and Frequency Patterns

Specific protocols exist for the timing and maximum allowed doses for both acute and intermittent use, characterizing the medicine’s role for symptomatic management.

Use Context	Standard Dose (MDI 100 µg actuation)	Procedural Limit
Acute Symptom Relief	Start with 1 actuation. May repeat with a second actuation after 5 minutes if breathing is not noticeably improved.	If symptoms are unrelieved after a total of 4 actuations, immediate medical consultation is required
Intermittent Symptom Management	1 to 2 actuations per administration.	Maximum daily limit of 8 actuations
Prevention of Exercise-Induced Bronchospasm	1 to 2 actuations administered 15 to 30 minutes before exercise.	Included within the 8 actuations maximum

Administration and Procedural Requirements

Since Fenoterol is used as an as-needed treatment, the concept of a missed dose does not apply. Use is conditional on the presence of symptoms or a preventative requirement. For pediatric use, the standard adult acute dosing regimen applies to children over 6 years, but administration must occur under adult supervision. If using the MDI, the device requires priming before first use or after a prolonged period of non-use. When the inhalation solution is used, it may require dilution with 0.9% sterile sodium chloride solution to reach the volume necessary for nebulization.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Susa

This overview summarizes the type of official research that has been conducted on Susa (Fenoterol) and what patterns have been observed in studies, while highlighting areas where evidence remains uncertain. This information is purely descriptive and does not offer medical advice.

Evidence for Acute Airway Narrowing in Asthma

The research exploring the use of Susa for sudden or acute symptoms related to asthma primarily includes short-term, randomized controlled trials (RCTs). Research examined the medicine's application in study populations that included both adults and children with reversible airway symptoms.

Studies focused on measuring key pulmonary functional outcomes such as Forced Expiratory Volume in 1 second ( FEV1) and Peak Expiratory Flow (PEF). These functional measures are used to assess the degree of airway response observed during the study period. Findings describe patterns observed in the studies that include measurements of these functional parameters over short time intervals (minutes to a few hours).

Because this compound has been in use for many years, many of the core studies are historical. Research focused on its role in current international management protocols is often limited. Follow-up durations were limited in these studies, meaning there is limited information for long-term outcomes of using Fenoterol as a standalone maintenance treatment.

Evidence for Symptom Management in COPD

Susa was studied for its use in conditions characterized by fluctuating or episodic manifestations, such as Chronic Obstructive Pulmonary Disease (COPD). Research has included RCTs and trials that examined Susa's use in fixed-dose combination products with other inhaled medicines. The research examined outcomes related to physical discomfort and outcomes reflecting daily functioning, such as changes in overall symptom severity.

A key limitation is that much of the available evidence is focused on the drug class generally, or specifically on the medicine's use as a combination therapy, which means comparative evidence for Susa alone in modern long-term COPD management is lacking. The evidence quality varies across studies, and data for certain groups remain insufficient within the COPD population studied.

Evidence for Preventing Exercise-Induced Breathing Difficulty

Studies explored the use of Susa for preventing breathing difficulty triggered by physical activity. These trials often used acute, controlled clinical challenge studies, where researchers examined the medicine's ability to provide bronchoprotection, measuring the degree of fall in lung function ( FEV1) after physical exertion.

Research offers limited insight into the long-term patterns or potential for decreased responsiveness when Susa is used regularly over an extended period for this specific preventative indication. The findings describe group patterns, not personal outcomes, and apply only to the populations studied.

Key Limitations and Areas of Uncertainty in the Research Base

The evidence for Susa contributes to understanding symptom patterns and short-term functional shifts. Key limitations include that many of the regulatory studies are historical, and research focused on the medicine's role in the context of modern long-term management protocols is often less characterized. Much of the current data is observational or focused on fixed-dose combination products rather than Fenoterol alone.

Frequently Asked Questions (FAQ)

Common questions about Susa (FAQ)

Q: Does Susa work right away or does it take time?

A: According to the official product information, Fenoterol is described as having a rapid onset of action. The medicine is designed to provide prompt bronchodilation (airway widening) for the immediate relief of acute breathing symptoms.

Q: Is Susa meant for long-term use?

A: Susa is formally classified as a short-acting bronchodilator intended for on-demand symptom relief. Official dosing protocols define its use for acute or intermittent needs, such as before exercise, and not as a long-term maintenance treatment for a chronic condition.

Q: Are there any common foods that should be avoided when taking Susa?

A: Official safety information indicates that intake of food with high sugar content and carbohydrates should be restricted while using this medication. This restriction is based on the potential for Susa to affect blood glucose levels.

Q: Does Susa affect sleep patterns?

A: Regulatory documents list the side effects of agitation and nervousness under Psychiatric disorders. Since Susa belongs to the sympathomimetic agent class of medications, it may cause effects on the central nervous system that could lead to general sleep disturbance.

Q: Can Susa be taken with supplements like vitamins or herbal products?

A: The official regulatory information indicates the importance of disclosing all medications, supplements, and herbal remedies to the prescribing professional. The product information also includes specific restrictions on alcohol consumption and notes caution regarding caffeine and diets high in sugar and carbohydrates.

Q: Is Susa known to interact with caffeine?

A: Official safety advice indicates that caffeine is a substance to be avoided or limited in the product profile. The restriction is noted because caffeine consumption may increase the risk of certain side effects, such as palpitations (fast or uneven heartbeat) and nervousness.

Q: Can older adults use Susa?

A: The official label advises caution for patients who have certain underlying conditions that are common in older adults, such as severe heart disorders or insufficiently controlled diabetes. The official label suggests that the use of Susa requires a careful risk-benefit assessment in these populations.

Q: Is Susa safe to use if someone has mild liver issues?

A: The label contraindicates use in severe hepatic impairment (severe liver problems). When mild liver issues are present, the use of Susa is subject to clinical judgment based on the individual patient profile.

Q: Is it possible to take Susa if I am lactose intolerant?

A: Susa is not a tablet or capsule, but is supplied as an inhalation solution or an aerosol via a Metered-Dose Inhaler (MDI). These specific types of formulations are unlikely to contain lactose as an inactive ingredient.

Q: What colors or markings are on the Susa pill?

A: Susa is not available in the form of a pill or tablet, so it does not have colors or markings typically found on oral medication. The product is supplied as an inhalation solution or an aerosol for a Metered-Dose Inhaler (MDI), which is a pressurized canister.

Q: Can Susa make existing anxiety worse?

A: As a sympathomimetic agent, Susa has the potential to cause stimulatory effects. Regulatory documents list agitation and nervousness among the possible side effects under the Psychiatric disorders category.

Q: Can taking Susa affect my mood?

A: Regulatory documents list side effects under Psychiatric disorders, which include agitation and nervousness. These documented effects are related to the mood and affect of the user.

Q: Does Susa affect blood sugar levels?

A: Official safety information indicates that Susa may cause an increase in blood glucose levels because it is a beta2-agonist. The product information notes a need for caution in patients with insufficiently controlled diabetes mellitus.

Q: How long after stopping Susa does the medicine typically leave the system?

A: Pharmacokinetic studies detailed in regulatory documents show that fenoterol is eliminated from the plasma in two phases. The terminal half-life—the time it takes for half the drug to be eliminated—is approximately 4.87 hours. The terminal half-life provides an estimate of the drug's elimination from the system.

Q: Can Susa be split or crushed if the pill is too large?

A: Susa is not available as a tablet or capsule that can be split or crushed. It is supplied as an inhalation solution or an aerosol for a Metered-Dose Inhaler (MDI). The product is designed to be used only via the appropriate inhalation device.

Q: Does Susa interact with common blood pressure medications?

A: Official drug information states that Susa interacts with several types of blood pressure medications. For instance, beta-blockers may reduce Susa's effectiveness, and certain diuretics can increase the risk of low potassium levels, known as hypokalemia.

Q: What are the main risks associated with Susa for patients with heart problems?

A: Regulatory documents list specific heart conditions that contraindicate the use of Susa, including Hypertrophic Obstructive Cardiomyopathy ( HOCM) and certain tachyarrhythmias (rapid heart rhythms). There is also a documented risk of arrhythmias when Susa is used alongside cardiac glycosides because the combination may cause low potassium.

Q: Is Susa considered a Schedule IV controlled substance?

A: According to U.S. and major international drug scheduling authorities, Susa (Fenoterol) is not classified as a federally controlled substance (e.g., Schedule I-V). This means it is not listed as having dependence or addiction potential under those regulatory systems.

Q: Why are there warnings about driving or operating machinery while on Susa?

A: The official product label includes an advisory that patients should use caution regarding activities like driving or operating machinery. This is because side effects such as dizziness have been reported in clinical trials and may impair motor skills or judgment.

Q: Does the time of day I take Susa matter?

A: Susa is designed as an as-needed treatment. Therefore, the time of day is generally less relevant than the presence of symptoms. The primary timing rule is that it must be taken 15 to 30 minutes before exercise when used for prevention.

Q: Are there known instances of Susa not working for certain patient groups?

A: Research evidence summarized in the regulatory documents indicates that data is limited or insufficient for certain patient groups, particularly regarding long-term outcomes of Susa as a standalone treatment in modern COPD management protocols.

How should Susa be stored and disposed of?

How to Store and Dispose of Susa?

Susa (Fenoterol MDI) must be stored and handled strictly according to the official regulatory instructions, which focus on the integrity and safety of the pressurized container.

Storage Requirements

The product must be stored in a cool and dry place and kept out of the reach of children. The pressurized canister must be protected from heat and direct sunlight. It is mandated that the container not be exposed to temperatures above 50 C and must not be pierced or opened by force.

Disposal Instructions

Disposal must adhere to pharmaceutical waste guidelines. Unused or expired Susa must not be thrown into the household trash or disposed of by pouring into wastewater or drains. The product and its container must be managed through an approved waste disposal plant or returned to a pharmacy, in accordance with local environmental regulations.

Susa